Immune modulation by danazol in autoimmune thrombocytopenia

Ravindra Mylvaganam, Yeon S. Ahn, William J. Harrington, Chae I. Kim

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Danazol, an attenuated androgen, has recently been introduced into the treatment of autoimmune thrombocytopenia. We studied its effects on T helper/inducer (Thi) and T suppressor/cytotoxic (Tsc) lymphocytes in these patients. Prospectively nine patients were studied with their T-cell subsets measured before and during danazol therapy. Increases in the percentage of Thi lymphocytes (P < 0.05) and Thi/Tsc ratios (P < 0.001) were observed at 1 and 3 months of treatment. Retrospectively T-cell subset data on 30 patients not treated with danazol and 36 patients on danazol were compared with those of 35 normal controls. The group not on danazol had lower percentages of Pan T (P < 0.05), Thi (P < 0.002), and Thi/Tsc ratios (P < 0.00005), and had higher percentages of Tsc lymphocytes (P < 0.01), than those of controls. In the group treated with danazol the percentages of Pan T, Thi, and Tsc lymphocytes were similar to those of controls. The percentage of Thi in the treated group was higher (P < 0.002) than in the untreated group. Thus, danazol appears to be an effective immune modulator, correcting the abnormality of T-cell subsets seen in autoimmune thrombocytopenia by increasing the percentage of Thi lymphocytes.

Original languageEnglish (US)
Pages (from-to)281-287
Number of pages7
JournalClinical Immunology and Immunopathology
Issue number3
StatePublished - Mar 1987

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pathology and Forensic Medicine
  • Immunology


Dive into the research topics of 'Immune modulation by danazol in autoimmune thrombocytopenia'. Together they form a unique fingerprint.

Cite this